Outlook Therapeutics, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2015 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Outlook Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2015 to Q2 2024.
  • Outlook Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2024 was $44.4M.
  • Outlook Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending June 30, 2024 was -$94M, a 55.9% decline year-over-year.
  • Outlook Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$59M, a 10.7% increase from 2022.
  • Outlook Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$66.1M, a 24.2% decline from 2021.
  • Outlook Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$53.2M, a 50.9% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 -$94M $44.4M +$65.1M Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-14
Q1 2024 -$159M -$114M -$108M -1618% Jan 1, 2024 Mar 31, 2024 10-Q 2024-08-14
Q4 2023 -$51.5M -$11.2M +$7.48M +40.1% Oct 1, 2023 Dec 31, 2023 10-Q 2024-08-14
Q3 2023 -$59M -$13M +$1.35M +9.44% Jul 1, 2023 Sep 30, 2023 10-K 2023-12-22
Q2 2023 -$60.3M -$20.7M -$3.14M -17.9% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-14
Q1 2023 -$57.2M -$6.65M +$13.1M +66.2% Jan 1, 2023 Mar 31, 2023 10-Q 2024-08-14
Q4 2022 -$70.3M -$18.7M -$4.2M -29% Oct 1, 2022 Dec 31, 2022 10-Q 2024-08-14
Q3 2022 -$66.1M -$14.3M -$941K -7.02% Jul 1, 2022 Sep 30, 2022 10-K 2023-12-22
Q2 2022 -$65.1M -$17.5M -$5.34M -43.8% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-14
Q1 2022 -$59.8M -$19.7M -$6.6M -50.3% Jan 1, 2022 Mar 31, 2022 10-Q 2023-08-14
Q4 2021 -$53.2M -$14.5M -$6.82K -0.05% Oct 1, 2021 Dec 31, 2021 10-Q 2023-08-14
Q3 2021 -$53.2M -$13.4M -$3.48M -35.1% Jul 1, 2021 Sep 30, 2021 10-K 2022-12-29
Q2 2021 -$49.7M -$12.2M -$9.18M -305% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-10
Q1 2021 -$40.5M -$13.1M -$7.41M -130% Jan 1, 2021 Mar 31, 2021 10-Q 2022-08-10
Q4 2020 -$33.1M -$14.5M +$2.15M +12.9% Oct 1, 2020 Dec 31, 2020 10-Q 2022-08-10
Q3 2020 -$35.2M -$9.92M +$175K +1.73% Jul 1, 2020 Sep 30, 2020 10-K 2021-12-23
Q2 2020 -$35.4M -$3.01M +$1.43M +32.1% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-13
Q1 2020 -$36.8M -$5.7M +$4.54M +44.4% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-14
Q4 2019 -$41.4M -$16.6M -$6.86M -70.4% Oct 1, 2019 Dec 31, 2019 10-Q 2021-02-16
Q3 2019 -$34.5M -$10.1M +$2.1M +17.2% Jul 1, 2019 Sep 30, 2019 10-K 2020-12-23
Q2 2019 -$36.6M -$4.44M +$3.99M +47.3% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-14
Q1 2019 -$40.6M -$10.2M -$2.7M -35.9% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-15
Q4 2018 -$37.9M -$9.74M -$7.82M -407% Oct 1, 2018 Dec 31, 2018 10-Q 2020-02-14
Q3 2018 -$30.1M -$12.2M -$5.83M -91.4% Jul 1, 2018 Sep 30, 2018 10-K 2019-12-19
Q2 2018 -$24.3M -$8.43M -$3.1M -58.2% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-14
Q1 2018 -$21.2M -$7.54M +$506K +6.29% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-15
Q4 2017 -$21.7M -$1.92M +$17.2M +89.9% Oct 1, 2017 Dec 31, 2017 10-Q 2019-02-14
Q3 2017 -$38.8M -$6.37M +$4.19M +39.7% Jul 1, 2017 Sep 30, 2017 10-K 2018-12-18
Q2 2017 -$43M -$5.33M +$17M +76.1% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-14
Q1 2017 -$60M -$8.05M -$4.5M -127% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-15
Q4 2016 -$55.5M -$19.1M -$2.23M -13.2% Oct 1, 2016 Dec 31, 2016 10-Q 2018-02-14
Q3 2016 -$53.3M -$10.6M Jul 1, 2016 Sep 30, 2016 10-K 2017-12-29
Q2 2016 -$22.3M -$11M -96.9% Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-14
Q1 2016 -$3.54M +$10.4M +74.7% Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-15
Q4 2015 -$16.9M Oct 1, 2015 Dec 31, 2015 10-Q 2017-02-14
Q2 2015 -$11.3M Apr 1, 2015 Jun 30, 2015 10-Q 2016-08-15
Q1 2015 -$14M Jan 1, 2015 Mar 31, 2015 10-Q 2016-06-27
* An asterisk sign (*) next to the value indicates that the value is likely invalid.